Terrain Pharmaceuticals

Terrain Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of innovative topical products for pain management. The company's lead asset was ZTlido (lidocaine topical system 1.8%), a next-generation medicated plaster designed to provide superior adhesion and drug delivery for the treatment of pain associated with post-herpetic neuralgia. In March 2016, Terrain was acquired by Scilex Pharmaceuticals, a subsidiary of Scilex Holding Company, to bolster their pain management portfolio. Following the acquisition, ZTlido received FDA approval and is currently marketed as a key treatment option in the chronic pain space. The company's strategy centered on utilizing the 505(b)(2) regulatory pathway to enhance the delivery of well-established analgesic agents.